ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gestational Diabetes Treatment Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-18S10374
Home | Market Reports | Health| Reproductive Health
Global Gestational Diabetes Treatment Market Insights Forecast to 2028
BUY CHAPTERS

Global Gestational Diabetes Treatment Market Research Report 2025

Code: QYRE-Auto-18S10374
Report
June 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Biocon Ltd.
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi
Sun Pharmaceutical Industries Limited.
Merck
Novartis
Adocia
Peptron
Astrazeneca plc
Pfizer Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
Injex Pharma AG
Daiichi Sankyo

Gestational Diabetes Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Gestational Diabetes Treatment Market

Gestational Diabetes Treatment Market

The global market for Gestational Diabetes Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby. However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus. It is the inability of insulin to absorb the sugars consumed as part of the meal. It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus. This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gestational Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Diabetes Treatment.
The Gestational Diabetes Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gestational Diabetes Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gestational Diabetes Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Gestational Diabetes Treatment Market Report

Report Metric Details
Report Name Gestational Diabetes Treatment Market
CAGR 5%
Segment by Type
  • Insulin
  • SGLT-2 Inhibitors
  • Alpha-glucosidase Inhibitors
  • Others
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis, Adocia, Peptron, AstraZeneca plc, Pfizer, Inc, Takeda Pharmaceutical Company Ltd, Abbott, Antares Pharma, INJEX Pharma AG, Daiichi Sankyo
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Gestational Diabetes Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Gestational Diabetes Treatment Market report?

Ans: The main players in the Gestational Diabetes Treatment Market are Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis, Adocia, Peptron, AstraZeneca plc, Pfizer, Inc, Takeda Pharmaceutical Company Ltd, Abbott, Antares Pharma, INJEX Pharma AG, Daiichi Sankyo

What are the Application segmentation covered in the Gestational Diabetes Treatment Market report?

Ans: The Applications covered in the Gestational Diabetes Treatment Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Gestational Diabetes Treatment Market report?

Ans: The Types covered in the Gestational Diabetes Treatment Market report are Insulin, SGLT-2 Inhibitors, Alpha-glucosidase Inhibitors, Others

Recommended Reports

Diabetes Management

Women's Health

Related Metabolic Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gestational Diabetes Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Insulin
1.2.3 SGLT-2 Inhibitors
1.2.4 Alpha-glucosidase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Gestational Diabetes Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gestational Diabetes Treatment Market Perspective (2020-2031)
2.2 Global Gestational Diabetes Treatment Growth Trends by Region
2.2.1 Global Gestational Diabetes Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gestational Diabetes Treatment Historic Market Size by Region (2020-2025)
2.2.3 Gestational Diabetes Treatment Forecasted Market Size by Region (2026-2031)
2.3 Gestational Diabetes Treatment Market Dynamics
2.3.1 Gestational Diabetes Treatment Industry Trends
2.3.2 Gestational Diabetes Treatment Market Drivers
2.3.3 Gestational Diabetes Treatment Market Challenges
2.3.4 Gestational Diabetes Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gestational Diabetes Treatment Players by Revenue
3.1.1 Global Top Gestational Diabetes Treatment Players by Revenue (2020-2025)
3.1.2 Global Gestational Diabetes Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Gestational Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gestational Diabetes Treatment Revenue
3.4 Global Gestational Diabetes Treatment Market Concentration Ratio
3.4.1 Global Gestational Diabetes Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gestational Diabetes Treatment Revenue in 2024
3.5 Global Key Players of Gestational Diabetes Treatment Head office and Area Served
3.6 Global Key Players of Gestational Diabetes Treatment, Product and Application
3.7 Global Key Players of Gestational Diabetes Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gestational Diabetes Treatment Breakdown Data by Type
4.1 Global Gestational Diabetes Treatment Historic Market Size by Type (2020-2025)
4.2 Global Gestational Diabetes Treatment Forecasted Market Size by Type (2026-2031)
5 Gestational Diabetes Treatment Breakdown Data by Application
5.1 Global Gestational Diabetes Treatment Historic Market Size by Application (2020-2025)
5.2 Global Gestational Diabetes Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gestational Diabetes Treatment Market Size (2020-2031)
6.2 North America Gestational Diabetes Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gestational Diabetes Treatment Market Size by Country (2020-2025)
6.4 North America Gestational Diabetes Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gestational Diabetes Treatment Market Size (2020-2031)
7.2 Europe Gestational Diabetes Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gestational Diabetes Treatment Market Size by Country (2020-2025)
7.4 Europe Gestational Diabetes Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gestational Diabetes Treatment Market Size (2020-2031)
8.2 Asia-Pacific Gestational Diabetes Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gestational Diabetes Treatment Market Size (2020-2031)
9.2 Latin America Gestational Diabetes Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gestational Diabetes Treatment Market Size by Country (2020-2025)
9.4 Latin America Gestational Diabetes Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gestational Diabetes Treatment Market Size (2020-2031)
10.2 Middle East & Africa Gestational Diabetes Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biocon Limited
11.1.1 Biocon Limited Company Details
11.1.2 Biocon Limited Business Overview
11.1.3 Biocon Limited Gestational Diabetes Treatment Introduction
11.1.4 Biocon Limited Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.1.5 Biocon Limited Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Gestational Diabetes Treatment Introduction
11.2.4 Eli Lilly Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Gestational Diabetes Treatment Introduction
11.3.4 Novo Nordisk Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Boehringer Ingelheim GmbH
11.4.1 Boehringer Ingelheim GmbH Company Details
11.4.2 Boehringer Ingelheim GmbH Business Overview
11.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Introduction
11.4.4 Boehringer Ingelheim GmbH Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.4.5 Boehringer Ingelheim GmbH Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Details
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Gestational Diabetes Treatment Introduction
11.5.4 Sanofi S.A. Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.5.5 Sanofi S.A. Recent Development
11.6 Sun Pharmaceutical Industries Limited
11.6.1 Sun Pharmaceutical Industries Limited Company Details
11.6.2 Sun Pharmaceutical Industries Limited Business Overview
11.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Introduction
11.6.4 Sun Pharmaceutical Industries Limited Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.6.5 Sun Pharmaceutical Industries Limited Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Gestational Diabetes Treatment Introduction
11.7.4 Merck Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Gestational Diabetes Treatment Introduction
11.8.4 Novartis Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.8.5 Novartis Recent Development
11.9 Adocia
11.9.1 Adocia Company Details
11.9.2 Adocia Business Overview
11.9.3 Adocia Gestational Diabetes Treatment Introduction
11.9.4 Adocia Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.9.5 Adocia Recent Development
11.10 Peptron
11.10.1 Peptron Company Details
11.10.2 Peptron Business Overview
11.10.3 Peptron Gestational Diabetes Treatment Introduction
11.10.4 Peptron Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.10.5 Peptron Recent Development
11.11 AstraZeneca plc
11.11.1 AstraZeneca plc Company Details
11.11.2 AstraZeneca plc Business Overview
11.11.3 AstraZeneca plc Gestational Diabetes Treatment Introduction
11.11.4 AstraZeneca plc Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.11.5 AstraZeneca plc Recent Development
11.12 Pfizer, Inc
11.12.1 Pfizer, Inc Company Details
11.12.2 Pfizer, Inc Business Overview
11.12.3 Pfizer, Inc Gestational Diabetes Treatment Introduction
11.12.4 Pfizer, Inc Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.12.5 Pfizer, Inc Recent Development
11.13 Takeda Pharmaceutical Company Ltd
11.13.1 Takeda Pharmaceutical Company Ltd Company Details
11.13.2 Takeda Pharmaceutical Company Ltd Business Overview
11.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Introduction
11.13.4 Takeda Pharmaceutical Company Ltd Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.13.5 Takeda Pharmaceutical Company Ltd Recent Development
11.14 Abbott
11.14.1 Abbott Company Details
11.14.2 Abbott Business Overview
11.14.3 Abbott Gestational Diabetes Treatment Introduction
11.14.4 Abbott Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.14.5 Abbott Recent Development
11.15 Antares Pharma
11.15.1 Antares Pharma Company Details
11.15.2 Antares Pharma Business Overview
11.15.3 Antares Pharma Gestational Diabetes Treatment Introduction
11.15.4 Antares Pharma Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.15.5 Antares Pharma Recent Development
11.16 INJEX Pharma AG
11.16.1 INJEX Pharma AG Company Details
11.16.2 INJEX Pharma AG Business Overview
11.16.3 INJEX Pharma AG Gestational Diabetes Treatment Introduction
11.16.4 INJEX Pharma AG Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.16.5 INJEX Pharma AG Recent Development
11.17 Daiichi Sankyo
11.17.1 Daiichi Sankyo Company Details
11.17.2 Daiichi Sankyo Business Overview
11.17.3 Daiichi Sankyo Gestational Diabetes Treatment Introduction
11.17.4 Daiichi Sankyo Revenue in Gestational Diabetes Treatment Business (2020-2025)
11.17.5 Daiichi Sankyo Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Biocon Ltd.
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi
Sun Pharmaceutical Industries Limited.
Merck
Novartis
Adocia
Peptron
Astrazeneca plc
Pfizer Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
Injex Pharma AG
Daiichi Sankyo
List of Tables
 Table 1. Global Gestational Diabetes Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Insulin
 Table 3. Key Players of SGLT-2 Inhibitors
 Table 4. Key Players of Alpha-glucosidase Inhibitors
 Table 5. Key Players of Others
 Table 6. Global Gestational Diabetes Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Gestational Diabetes Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Gestational Diabetes Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Gestational Diabetes Treatment Market Share by Region (2020-2025)
 Table 10. Global Gestational Diabetes Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Gestational Diabetes Treatment Market Share by Region (2026-2031)
 Table 12. Gestational Diabetes Treatment Market Trends
 Table 13. Gestational Diabetes Treatment Market Drivers
 Table 14. Gestational Diabetes Treatment Market Challenges
 Table 15. Gestational Diabetes Treatment Market Restraints
 Table 16. Global Gestational Diabetes Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Gestational Diabetes Treatment Market Share by Players (2020-2025)
 Table 18. Global Top Gestational Diabetes Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gestational Diabetes Treatment as of 2024)
 Table 19. Ranking of Global Top Gestational Diabetes Treatment Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Gestational Diabetes Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Gestational Diabetes Treatment, Headquarters and Area Served
 Table 22. Global Key Players of Gestational Diabetes Treatment, Product and Application
 Table 23. Global Key Players of Gestational Diabetes Treatment, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Gestational Diabetes Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Gestational Diabetes Treatment Revenue Market Share by Type (2020-2025)
 Table 27. Global Gestational Diabetes Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Gestational Diabetes Treatment Revenue Market Share by Type (2026-2031)
 Table 29. Global Gestational Diabetes Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Gestational Diabetes Treatment Revenue Market Share by Application (2020-2025)
 Table 31. Global Gestational Diabetes Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Gestational Diabetes Treatment Revenue Market Share by Application (2026-2031)
 Table 33. North America Gestational Diabetes Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Gestational Diabetes Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Gestational Diabetes Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Gestational Diabetes Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Gestational Diabetes Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Gestational Diabetes Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Gestational Diabetes Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Gestational Diabetes Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Gestational Diabetes Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Gestational Diabetes Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Gestational Diabetes Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Biocon Limited Company Details
 Table 49. Biocon Limited Business Overview
 Table 50. Biocon Limited Gestational Diabetes Treatment Product
 Table 51. Biocon Limited Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 52. Biocon Limited Recent Development
 Table 53. Eli Lilly Company Details
 Table 54. Eli Lilly Business Overview
 Table 55. Eli Lilly Gestational Diabetes Treatment Product
 Table 56. Eli Lilly Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 57. Eli Lilly Recent Development
 Table 58. Novo Nordisk Company Details
 Table 59. Novo Nordisk Business Overview
 Table 60. Novo Nordisk Gestational Diabetes Treatment Product
 Table 61. Novo Nordisk Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 62. Novo Nordisk Recent Development
 Table 63. Boehringer Ingelheim GmbH Company Details
 Table 64. Boehringer Ingelheim GmbH Business Overview
 Table 65. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product
 Table 66. Boehringer Ingelheim GmbH Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 67. Boehringer Ingelheim GmbH Recent Development
 Table 68. Sanofi S.A. Company Details
 Table 69. Sanofi S.A. Business Overview
 Table 70. Sanofi S.A. Gestational Diabetes Treatment Product
 Table 71. Sanofi S.A. Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 72. Sanofi S.A. Recent Development
 Table 73. Sun Pharmaceutical Industries Limited Company Details
 Table 74. Sun Pharmaceutical Industries Limited Business Overview
 Table 75. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product
 Table 76. Sun Pharmaceutical Industries Limited Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 77. Sun Pharmaceutical Industries Limited Recent Development
 Table 78. Merck Company Details
 Table 79. Merck Business Overview
 Table 80. Merck Gestational Diabetes Treatment Product
 Table 81. Merck Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 82. Merck Recent Development
 Table 83. Novartis Company Details
 Table 84. Novartis Business Overview
 Table 85. Novartis Gestational Diabetes Treatment Product
 Table 86. Novartis Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 87. Novartis Recent Development
 Table 88. Adocia Company Details
 Table 89. Adocia Business Overview
 Table 90. Adocia Gestational Diabetes Treatment Product
 Table 91. Adocia Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 92. Adocia Recent Development
 Table 93. Peptron Company Details
 Table 94. Peptron Business Overview
 Table 95. Peptron Gestational Diabetes Treatment Product
 Table 96. Peptron Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 97. Peptron Recent Development
 Table 98. AstraZeneca plc Company Details
 Table 99. AstraZeneca plc Business Overview
 Table 100. AstraZeneca plc Gestational Diabetes Treatment Product
 Table 101. AstraZeneca plc Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 102. AstraZeneca plc Recent Development
 Table 103. Pfizer, Inc Company Details
 Table 104. Pfizer, Inc Business Overview
 Table 105. Pfizer, Inc Gestational Diabetes Treatment Product
 Table 106. Pfizer, Inc Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 107. Pfizer, Inc Recent Development
 Table 108. Takeda Pharmaceutical Company Ltd Company Details
 Table 109. Takeda Pharmaceutical Company Ltd Business Overview
 Table 110. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product
 Table 111. Takeda Pharmaceutical Company Ltd Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 112. Takeda Pharmaceutical Company Ltd Recent Development
 Table 113. Abbott Company Details
 Table 114. Abbott Business Overview
 Table 115. Abbott Gestational Diabetes Treatment Product
 Table 116. Abbott Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 117. Abbott Recent Development
 Table 118. Antares Pharma Company Details
 Table 119. Antares Pharma Business Overview
 Table 120. Antares Pharma Gestational Diabetes Treatment Product
 Table 121. Antares Pharma Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 122. Antares Pharma Recent Development
 Table 123. INJEX Pharma AG Company Details
 Table 124. INJEX Pharma AG Business Overview
 Table 125. INJEX Pharma AG Gestational Diabetes Treatment Product
 Table 126. INJEX Pharma AG Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 127. INJEX Pharma AG Recent Development
 Table 128. Daiichi Sankyo Company Details
 Table 129. Daiichi Sankyo Business Overview
 Table 130. Daiichi Sankyo Gestational Diabetes Treatment Product
 Table 131. Daiichi Sankyo Revenue in Gestational Diabetes Treatment Business (2020-2025) & (US$ Million)
 Table 132. Daiichi Sankyo Recent Development
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Gestational Diabetes Treatment Picture
 Figure 2. Global Gestational Diabetes Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Gestational Diabetes Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Insulin Features
 Figure 5. SGLT-2 Inhibitors Features
 Figure 6. Alpha-glucosidase Inhibitors Features
 Figure 7. Others Features
 Figure 8. Global Gestational Diabetes Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Gestational Diabetes Treatment Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Pharmacies Case Studies
 Figure 11. Retail Pharmacies Case Studies
 Figure 12. Online Pharmacies Case Studies
 Figure 13. Gestational Diabetes Treatment Report Years Considered
 Figure 14. Global Gestational Diabetes Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Gestational Diabetes Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Gestational Diabetes Treatment Market Share by Region: 2024 VS 2031
 Figure 17. Global Gestational Diabetes Treatment Market Share by Players in 2024
 Figure 18. Global Top Gestational Diabetes Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gestational Diabetes Treatment as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Gestational Diabetes Treatment Revenue in 2024
 Figure 20. North America Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Gestational Diabetes Treatment Market Share by Country (2020-2031)
 Figure 22. United States Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Gestational Diabetes Treatment Market Share by Country (2020-2031)
 Figure 26. Germany Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Gestational Diabetes Treatment Market Share by Region (2020-2031)
 Figure 34. China Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Gestational Diabetes Treatment Market Share by Country (2020-2031)
 Figure 42. Mexico Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Gestational Diabetes Treatment Market Share by Country (2020-2031)
 Figure 46. Turkey Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Gestational Diabetes Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Biocon Limited Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 50. Eli Lilly Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 51. Novo Nordisk Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 52. Boehringer Ingelheim GmbH Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 53. Sanofi S.A. Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 54. Sun Pharmaceutical Industries Limited Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 55. Merck Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 56. Novartis Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 57. Adocia Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 58. Peptron Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 59. AstraZeneca plc Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 60. Pfizer, Inc Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 61. Takeda Pharmaceutical Company Ltd Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 62. Abbott Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 63. Antares Pharma Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 64. INJEX Pharma AG Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 65. Daiichi Sankyo Revenue Growth Rate in Gestational Diabetes Treatment Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Diabetes Devices and Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Care Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Digital Diabetes Care Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Management Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Wearables Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetic Lancets Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Continuous Glucose Monitoring CGM Systems for Diabetics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Portable Blood Glucose Meter Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glucose Meters Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Continuous Glucose Monitoring CGM System for Diabetes Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glucagon Injectable Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycated Hemoglobin Control Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Management Insulin Pump and Continuous Glucose Monitors CGM Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Low Glycemic Index Sugar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Networked Glucose Meter Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Continuous Non invasive Glucose Monitoring System for Diabetes Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Food for Special Diets for Diabetics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Perinatal Infections Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions